Changeflow GovPing Pharma & Drug Safety Aminopyridine compound as aldehyde trapping agent
Routine Notice Added Final

Aminopyridine compound as aldehyde trapping agent

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

USPTO granted Patent US12595259B2 to Zhuhai United Laboratories Co., Ltd. for an aminopyridine compound functioning as an aldehyde trapping agent, including formula (I) and its pharmaceutically acceptable salts. The patent covers 18 claims and has applications in ophthalmic therapeutics.

What changed

USPTO issued Patent US12595259B2 granting Zhuhai United Laboratories Co., Ltd. exclusive rights to an aminopyridine compound for aldehyde trapping applications. The patent contains 18 claims covering the compound of formula (I), its salts, and pharmaceutical compositions. Filing date was June 17, 2021, with the patent now formally granted.

For pharmaceutical companies and drug manufacturers, this patent establishes IP protection for a specific aminopyridine-based aldehyde trapping agent with ophthalmic applications (A61P 27/00, A61P 27/04). Parties developing competing aldehyde trapping agents or ophthalmic therapeutics should assess freedom-to-operate implications to avoid infringement on the granted claims.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Aminopyridine compound

Grant US12595259B2 Kind: B2 Apr 07, 2026

Assignee

ZHUHAI UNITED LABORATORIES CO., LTD.

Inventors

Peng Li, Chong Su, Xiaolin Li, Zhi Luo, Haiying He, Guoping Hu, Jian Li, Shuhui Chen

Abstract

An aminopyridine compound that may be used as an aldehyde trapping agent, and specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

CPC Classifications

C07D 213/74 C07D 401/04 C07D 401/06 C07D 401/12 C07D 407/04 C07D 409/04 C07D 413/04 C07D 417/04 A61K 31/443 A61K 31/4436 A61K 31/4439 A61K 31/444 A61K 31/4418 A61K 31/4412 A61P 27/00 A61P 27/04

Filing Date

2021-06-17

Application No.

18000684

Claims

18

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12595259B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!